ImmunoPrecise Antibodies Ltd. Cash Flow Conversion Efficiency
ImmunoPrecise Antibodies Ltd. cash flow conversion efficiency. Based on the latest financial reports, ImmunoPrecise Antibodies Ltd. (HYFT) has a cash flow conversion efficiency ratio of -0.162x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.87 Million) by net assets ($17.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ImmunoPrecise Antibodies Ltd. (1997–2025)
Cash flow conversion efficiency of ImmunoPrecise Antibodies Ltd. from 1997 to 2025. This chart illustrates how ImmunoPrecise Antibodies Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View HYFT stock price and chart for real-time trading data and today's change.
ImmunoPrecise Antibodies Ltd. Cash Flow Conversion Ratio Explained
ImmunoPrecise Antibodies Ltd. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ImmunoPrecise Antibodies Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ImmunoPrecise Antibodies Ltd. ranked by their cash flow conversion efficiency. Also see ImmunoPrecise Antibodies Ltd. market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
flyExclusive, Inc.
NYSE:FLYX
|
-0.007x |
|
Cloud Air Co.Ltd
KQ:036170
|
0.001x |
|
Battery Mineral Resources Corp
V:BMR
|
0.045x |
|
Nam Kwang Cons
KO:001260
|
-0.101x |
|
DDC Enterprise Limited
NYSE MKT:DDC
|
-0.021x |
|
Marketwise Inc
NASDAQ:MKTW
|
-0.084x |
|
Pangaea Oncology S.A.
MC:PANG
|
-0.057x |
|
Meiwu Technology Co Ltd
NASDAQ:WNW
|
0.047x |
Annual Cash Flow Conversion Efficiency for ImmunoPrecise Antibodies Ltd. (1997–2025)
The table below shows the annual cash flow conversion efficiency of ImmunoPrecise Antibodies Ltd. from 1997 to 2025. Review HYFT free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $23.63 Million | $-6.41 Million | -0.271x | -116.75% |
| 2024-04-30 | $33.92 Million | $-4.25 Million | -0.125x | +63.52% |
| 2023-04-30 | $57.80 Million | $-19.83 Million | -0.343x | -159.84% |
| 2022-04-30 | $75.13 Million | $-9.92 Million | -0.132x | -1152.78% |
| 2021-04-30 | $56.92 Million | $-600.00K | -0.011x | +88.57% |
| 2020-04-30 | $15.09 Million | $-1.39 Million | -0.092x | +48.03% |
| 2019-04-30 | $18.07 Million | $-3.21 Million | -0.177x | +34.01% |
| 2018-04-30 | $12.70 Million | $-3.42 Million | -0.269x | -15.23% |
| 2017-04-30 | $3.09 Million | $-721.65K | -0.233x | -174.62% |
| 2016-04-30 | $908.26K | $284.09K | 0.313x | +80.64% |
| 2015-04-30 | $-208.52K | $-36.11K | 0.173x | -40.10% |
| 2014-04-30 | $-161.21K | $-46.60K | 0.289x | +1338.08% |
| 2013-04-30 | $-215.66K | $-4.33K | 0.020x | -98.18% |
| 2012-04-30 | $-119.89K | $-132.72K | 1.107x | +273.25% |
| 2011-04-30 | $125.81K | $-80.39K | -0.639x | -1011.31% |
| 2010-04-30 | $5.37 Million | $-308.49K | -0.057x | -150.56% |
| 2009-04-30 | $6.78 Million | $-155.68K | -0.023x | +77.54% |
| 2008-04-30 | $5.12 Million | $-523.45K | -0.102x | -85.67% |
| 2007-04-30 | $5.40 Million | $-297.31K | -0.055x | -94.49% |
| 2006-04-30 | $3.91 Million | $-110.59K | -0.028x | -45.53% |
| 2005-04-30 | $4.23 Million | $-82.20K | -0.019x | +84.83% |
| 2004-04-30 | $1.39 Million | $-178.69K | -0.128x | +30.59% |
| 2003-04-30 | $912.21K | $-168.38K | -0.185x | +54.45% |
| 2002-04-30 | $691.56K | $-280.23K | -0.405x | -1206.41% |
| 2001-04-30 | $262.24K | $-8.13K | -0.031x | +94.10% |
| 2000-04-30 | $396.53K | $-208.54K | -0.526x | -319.83% |
| 1999-04-30 | $1.62 Million | $-202.94K | -0.125x | -58.13% |
| 1998-04-30 | $2.86 Million | $-226.81K | -0.079x | -165.55% |
| 1997-04-30 | $3.63 Million | $-108.20K | -0.030x | -- |
About ImmunoPrecise Antibodies Ltd.
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock ther… Read more